What Novartis (NVS) Said on Its Q3 Earnings Call
Novartis (NVS) raised its full-year 2026 core operating income outlook to flat to low-double-digit growth. The company reported strong sales growth for Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix. Novartis also updated its peak-sales forecast for Rhapsido to over $4 billion. Pipeline updates included positive data for remibrutinib and setbacks for del-desiran and pelacarsen. The company repurchased $2.8 billion in shares and completed acquisitions.
How this was made
The 30-second read
Why it matters
The guidance lift and strong product sales are likely to attract buying interest, while the disclosed buyback adds further support.
Market read
First‑report earnings guidance upgrade for a large‑cap pharma, material for traders.
What to watch
Potential headwinds from upcoming generic competition on Entresto and Xolair biosimilars could temper growth.
Background
Novartis detailed Q3 performance, highlighted double‑digit sales growth for several key products, and announced a $2.8 bn share repurchase.
Ticker impact
Novartis raised its full-year 2026 core operating income outlook to flat‑low double‑digit growth and reported strong sales growth across multiple drugs.
likely upward pressure as investors price in higher earnings outlook
The company moved from a low‑single‑digit decline forecast to flat‑low double‑digit growth, a material shift that typically lifts share price.
Market effects
Positive outlook may boost broader pharma and biotech sentiment.
European and Swiss markets could see modest gains from the upbeat guidance.
Adds to overall positive risk‑on bias in healthcare equities.
Counterpoint
If the guidance upgrade is already priced in, the stock may face a short‑term pull‑back.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant reporting Q3 results and guidance.
